Coloplast stock reacts to JPMorgan downgrade and lower price target

Published on 09/11/2026 at 13:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Coloplast stock came under pressure on Nasdaq Copenhagen on September 9, 2026 after JPMorgan cut its rating to Underweight and lowered its December 2027 price target to DKK 377 from DKK 484. The shares traded around DKK 431.90 that day, about 11 percent below their 52-week high of DKK 484.

Pop-Art-Comic-Illustration einer lächelnden Pflegekraft mit medizinischen Pflegeprodukten — Coloplast A/S (DK0060448595) als Medizintechnik-Firma inspiriert diese farbenfrohe Pop-Art-Comic-Szene mit einer freundlichen Pflegekraft dargestellt, Illustration mit AI erstellt.

Coloplast stock (ISIN DK0060448595) faced renewed attention after a sharp analyst downgrade from JPMorgan that fed into trading on Nasdaq Copenhagen on September 9, 2026. According to Ad-hoc-news on September 10, 2026, JPMorgan cut its rating on Coloplast from Neutral to Underweight and lowered its December 2027 price target to DKK 377 from DKK 484, a reduction of about 22 percent that immediately influenced sentiment toward the shares.

JPMorgan cuts rating and price target

The downgrade by JPMorgan is the most recent catalyst for Coloplast stock and adds a clear analyst voice to the debate about the Danish medical devices group’s valuation. As Ad-hoc-news reports, JPMorgan’s December 2027 price target of DKK 377 implies downside versus the trading level around DKK 431.90 observed on Nasdaq Copenhagen on September 9, 2026, and the cut from DKK 484 represents a drop of roughly DKK 107 per share. For investors, that 22 percent reduction in the target is a quantitative signal that the bank sees slower upside or increased risks compared with earlier expectations.

According to the same overview from Ad-hoc-news, Coloplast stock traded near DKK 431.90 on Nasdaq Copenhagen during the September 9, 2026 session, with an intraday low of DKK 427.80 as the downgrade was digested in the market. That level placed the shares around 11 percent below the previous DKK 484 price target that JPMorgan had held, and it also stood above the newly set DKK 377 target, highlighting the gap between current market pricing and the more cautious analyst view.

Recent financial performance and guidance context

To put the downgrade into perspective, investors typically look at Coloplast’s most recent reported financial figures and guidance, which are published on the company’s investor relations pages. According to Coloplast, the company regularly reports sales, earnings and margin trends for its core segments such as ostomy care, continence care and wound care, along with forward-looking guidance. These figures and projections form the basis for analyst models like JPMorgan’s and help explain why a bank might adjust its price target when growth, profitability or investment needs change.

Coloplast’s investor relations material also emphasizes long-term structural demand for its products, pointing to demographic trends such as aging populations and chronic disease prevalence that support steady volume growth over time per the overview on Coloplast. From an investor perspective, such structural drivers can offset near-term pressure from pricing, competition or regulatory changes, but they do not eliminate the relevance of quarterly execution or margin development that analysts scrutinize closely when setting ratings and price targets.

Stock level and implied downside

Per the trading snapshot cited by Ad-hoc-news, the price of Coloplast stock around DKK 431.90 on Nasdaq Copenhagen as of September 9, 2026 reflects a market capitalization that remains above the level implied by JPMorgan’s DKK 377 target, signaling that other investors or analyst houses may take a more optimistic view of the company’s future cash flows. The roughly DKK 54 difference between the trading price and the new target equates to about 12.5 percent implied downside from that specific analyst’s standpoint.

For retail investors following Coloplast stock, the key quantitative points are therefore clear: a December 2027 price target reduced from DKK 484 to DKK 377, a rating cut to Underweight and a share price near DKK 431.90 on September 9, 2026 that sits above the new target but below the old one. These numbers frame the debate around valuation and risk, and they illustrate how a single analyst move can recalibrate market expectations even when the underlying business is supported by long-term healthcare demand as described on Coloplast.